Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 81-8973 prophylaxis versus on-demand treatment in severe hemophilia A
2009-012150-20Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of octocog alfa in hemophilia A (2 arms), sponsored by Bayer. Primary endpoints: Superiority of prophylaxis over on-demand therapy by bleeding rate reduction and Bleeding rate comparison between prophylaxis and on-demand treatment. Started Oct 2010; status: completed.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2009-012150-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012150-20.